MA35132B1 - 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine - Google Patents

4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine

Info

Publication number
MA35132B1
MA35132B1 MA36460A MA36460A MA35132B1 MA 35132 B1 MA35132 B1 MA 35132B1 MA 36460 A MA36460 A MA 36460A MA 36460 A MA36460 A MA 36460A MA 35132 B1 MA35132 B1 MA 35132B1
Authority
MA
Morocco
Prior art keywords
triazine
aryl
phenyl
amines containing
sulfoximine group
Prior art date
Application number
MA36460A
Other languages
English (en)
Inventor
Ulrich Lücking
Rolf Bohlmann
Arne Scholz
Gerhard Siemeister
Mark Jean Gnoth
Ulf Bömer
Dirk Kosemund
Philip Lienau
Gerd Rühter
Carsten Schultz-Fademrecht
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35132(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP11167317A external-priority patent/EP2527332A1/fr
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA35132B1 publication Critical patent/MA35132B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/44—One nitrogen atom with halogen atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

La présente invention concerne des 4-aryl-n-phényl-1,3,5-triazine-2-amines contenant un groupe sulfoximine de formule générale (i) ou (ia) telles que décrites et définies dans le présent document, et leurs procédés de préparation, leur utilisation pour le traitement et/ou la prophylaxie de maladies, notamment de maladies hyper-prolifératives et/ou de maladies infectieuses induites par des virus et/ou de maladies cardiovasculaires. L'invention concerne également des composés intermédiaires utiles pour la préparation desdits composés de formule générale (i) ou (ia).
MA36460A 2011-05-24 2013-11-22 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine MA35132B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11167317A EP2527332A1 (fr) 2011-05-24 2011-05-24 4-Aryl-N-phényl-1,3,5-triazin-2-amines portant un groupe sulfoximine en tant qu'inhibiteurs de CDK9
EP11180759 2011-09-09
EP12158030 2012-03-05
PCT/EP2012/059399 WO2012160034A1 (fr) 2011-05-24 2012-05-21 4-aryl-n-phényl-1,3,5-triazine-2-amines contenant un groupe sulfoximine

Publications (1)

Publication Number Publication Date
MA35132B1 true MA35132B1 (fr) 2014-05-02

Family

ID=46085997

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36460A MA35132B1 (fr) 2011-05-24 2013-11-22 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine

Country Status (41)

Country Link
US (2) US9669034B2 (fr)
EP (1) EP2714654B1 (fr)
JP (1) JP5955948B2 (fr)
KR (1) KR101958501B1 (fr)
CN (1) CN103702979B (fr)
AP (1) AP3884A (fr)
AR (1) AR086552A1 (fr)
AU (1) AU2012260983B2 (fr)
BR (1) BR112013029976A2 (fr)
CA (1) CA2837027C (fr)
CL (1) CL2013003360A1 (fr)
CO (1) CO6811860A2 (fr)
CR (1) CR20130620A (fr)
CU (1) CU24175B1 (fr)
CY (1) CY1116791T1 (fr)
DK (1) DK2714654T3 (fr)
DO (1) DOP2013000277A (fr)
EA (1) EA023418B1 (fr)
EC (1) ECSP13013040A (fr)
ES (1) ES2549529T3 (fr)
GT (1) GT201300293A (fr)
HR (1) HRP20151060T1 (fr)
HU (1) HUE027853T2 (fr)
IL (1) IL229314A (fr)
JO (1) JO3204B1 (fr)
MA (1) MA35132B1 (fr)
ME (1) ME02227B (fr)
MX (1) MX340803B (fr)
MY (1) MY165748A (fr)
PE (1) PE20141075A1 (fr)
PL (1) PL2714654T3 (fr)
PT (1) PT2714654E (fr)
RS (1) RS54264B1 (fr)
SG (2) SG10201606952XA (fr)
SI (1) SI2714654T1 (fr)
TN (1) TN2013000485A1 (fr)
TW (2) TWI555737B (fr)
UA (1) UA112870C2 (fr)
UY (1) UY34095A (fr)
WO (1) WO2012160034A1 (fr)
ZA (1) ZA201309672B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
TWI691493B (zh) 2009-06-29 2020-04-21 美商阿吉歐斯製藥公司 治療化合物及組成物
EP2491145B1 (fr) 2009-10-21 2016-03-09 Agios Pharmaceuticals, Inc. Procédés et compositions pour des troubles relatifs à la prolifération cellulaire
ME03074B (fr) 2011-05-03 2019-01-20 Agios Pharmaceuticals Inc Activateurs de la pyruvate kinase destinés à être utilisés en thérapie
TWI555737B (zh) * 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CA2848615C (fr) * 2011-09-16 2020-02-25 Bayer Intellectual Property Gmbh Derives de 5-fluoropyrimidine disubstitues contenant un groupe sulfoximine
CN104114543B (zh) 2012-01-06 2019-03-15 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
EP2906212A4 (fr) 2012-10-15 2016-06-08 Agios Pharmaceuticals Inc Composés et compositions thérapeutiques
CA2917096C (fr) * 2013-07-04 2021-05-18 Bayer Pharma Aktiengesellschaft Derives 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine substitues par un groupe sulfoximine et leur utilisation comme inhibiteurs de la cdk9 kinase
CA2917671A1 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composes de 2,4 ou de 4,6-diaminopyrimidine en tant qu'inhibiteurs des mutants idh2 pour le traitement du cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
WO2015006592A1 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés de n,6-bis(aryl- ou hétéroaryl)-1,3,5-triazine-2,4-diamine à titre d'inhibiteurs des mutants idh2 pour le traitement du cancer
WO2015003360A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CN106232596A (zh) * 2014-03-13 2016-12-14 拜耳医药股份有限公司 含有砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物
AU2015229214B2 (en) 2014-03-14 2019-07-11 Les Laboratoires Servier Pharmaceutical compositions of therapeutically active compounds
US20170368069A1 (en) * 2015-01-13 2017-12-28 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n--1,3,5-triazin-2-amine for treating leukemias
WO2016150902A1 (fr) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Utilisation de 4-(4-fluoro-2-méthoxyphényl)-n-{3-[(s-méthylsulfonimidoyl)méthyl]phényl}-1,3,5-triazin-2-amine pour le traitement de cancers gastriques
US20180078560A1 (en) * 2015-03-24 2018-03-22 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating multiple myeloma
CN107427520A (zh) 2015-03-24 2017-12-01 拜耳医药股份有限公司 4‑(4‑氟‑2‑甲氧基苯基)‑n‑{3‑[(s‑甲基磺酰亚氨基)甲基]苯基}‑1，3，5‑三嗪‑2‑胺用于治疗淋巴瘤的用途
EP3294740B1 (fr) 2015-05-08 2019-09-04 H. Hoffnabb-La Roche Ag Nouveaux composés sulfonimidoylpurinone et dérivés pour le traitement et la prophylaxie d'infection virale
EP4344703A1 (fr) 2015-06-11 2024-04-03 Agios Pharmaceuticals, Inc. Procédés d'utilisation d'activateurs de la pyruvate kinase
PT3362066T (pt) 2015-10-15 2021-11-16 Celgene Corp Terapia de combinação para tratar malignidades
EP3362065B1 (fr) 2015-10-15 2024-04-03 Les Laboratoires Servier Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë
ES2834051T3 (es) 2016-04-06 2021-06-16 Innovative Molecules Gmbh Derivados de aminotiazol útiles como agentes antivirales
WO2018156443A1 (fr) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Nouveaux composés de sulfoximine substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
AU2018344471B2 (en) 2017-10-05 2022-09-29 Innovative Molecules Gmbh Enantiomers of substituted thiazoles as antiviral compounds
AU2019221019A1 (en) 2018-02-13 2020-07-23 Bayer Aktiengesellschaft Use of 5-Fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CA3172328A1 (fr) 2020-03-27 2021-09-30 Haruhisa Inoue Inhibiteur de degenerescence de cellules nerveuses
EP4174077A1 (fr) * 2021-10-27 2023-05-03 Merck Patent GmbH Dispositif de commutation électronique

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1030660A (en) 1912-06-25 Henry C Hunt Tool for removing floors, siding, scaffolds, &c.
GB1307271A (en) 1970-06-25 1973-02-14 Shell Int Research Sulphoximine derivatives and their use in herbicidal compositions
EP1218360B1 (fr) 1999-10-07 2008-05-28 Amgen Inc., Inhibiteurs de triazine kinase
SI2311825T1 (sl) * 2000-12-21 2016-02-29 Novartis Ag Pirimidinamini kot angiogenetski modulatorji
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
WO2003037346A1 (fr) 2001-10-31 2003-05-08 Cell Therapeutics, Inc. Derives de 6-phenyl-n-phenyl-(1,3,5)-triazine-2,4-diamine et composes apparentes ayant un effet inhibiteur de l'acide lysophosphatidique acyltransferase beta (lpaat-beta) et destines a etre utilises pour traiter le cancer
HUE029020T2 (en) 2002-07-18 2017-02-28 Janssen Pharmaceutica Nv Substituted triazine kinase inhibitors
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
EP1611125A1 (fr) 2003-02-07 2006-01-04 Vertex Pharmaceuticals Incorporated Pyrroles a substitution heteroaryle servant d'inhibiteurs de proteines kinases
WO2005026129A1 (fr) 2003-09-15 2005-03-24 Gpc Biotech Ag Derives d'aminopyrimidine a disubstitution 4,6 actifs sur le plan pharmaceutique en tant que modulateurs des proteine kinases
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
MX2007007272A (es) 2004-12-17 2007-07-11 Astrazeneca Ab 4-(4-imidazol-4-il)pirimidin-2-ilamino)benzamidas como inhibidores de cdk.
WO2007023507A2 (fr) 2005-06-20 2007-03-01 Wockhardt Limited Composition a activite antimicrobienne supportant des oxazolidinones ainsi que procedes de preparation associes
DE102005062742A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
EP1803723A1 (fr) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft Dérivés (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximide en tant qu'inhibiteurs de la kinase aurora pour le traitement de cancer
TW201309635A (zh) 2006-02-10 2013-03-01 Dow Agrosciences Llc 殺蟲性之ｎ-取代（６-鹵烷基吡啶-３-基）烷基磺醯亞胺（二）
JP4305477B2 (ja) 2006-07-25 2009-07-29 トヨタ自動車株式会社 火花点火式内燃機関
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
WO2008060248A1 (fr) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Pyrimidines substituées par indole, et leur utilisation dans le traitement d'un cancer
EP2094681A1 (fr) 2006-12-22 2009-09-02 Novartis AG Dérivés d'indol-4-yl-pyrimidinyl-2-yl-amine et leur utilisation comme inhibiteurs de la kinase dépendante des cyclines
JP2010514689A (ja) * 2006-12-22 2010-05-06 ノバルティス アーゲー 癌、炎症およびウイルス感染症の処置のためのｃｄｋ阻害剤としてのヘテロアリール−ヘテロアリール化合物
RS54533B1 (en) 2007-03-12 2016-06-30 Ym Biosciences Australia Pty Ltd PHENYL AMINOPYRIMIDINE COMPOUNDS AND THEIR APPLICATIONS
US8507498B2 (en) 2007-04-24 2013-08-13 Ingenium Pharmaceuticals Gmbh 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
JP5379787B2 (ja) 2007-04-24 2013-12-25 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
JP5693951B2 (ja) 2007-04-24 2015-04-01 アストラゼネカ エービー プロテインキナーゼの阻害剤
WO2008132138A1 (fr) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Dérivés d'aminopyrimidines disubstituées en 4 et en 6
BRPI0814775A2 (pt) 2007-07-20 2014-09-30 Dow Agrosciences Llc Vigor de planta crescente
WO2009032861A1 (fr) 2007-09-04 2009-03-12 The Scripps Research Institute Pyrimidinyl-amines substituées en tant qu'inhibiteurs de la protéine kinase
WO2009029998A1 (fr) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Composés rétrométaboliques
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
EP2179991A1 (fr) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Dérivés d'anilino-pyrimidine substitués par sulfoximine en tant qu'inhibiteurs de CDK, leur fabrication et leur utilisation en tant que médicaments
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
CA2777762A1 (fr) 2009-10-12 2011-04-21 Myrexis, Inc. Composes d'amino-pyrimidine en tant qu'inhibiteurs de tbkl et ou d'ikk epsilon
EP2550257B1 (fr) 2010-03-22 2016-12-21 Lead Discovery Center GmbH Dérivés de triazine disubstitué utilisés comme pharmaceutiques
EP2680852A1 (fr) 2011-03-02 2014-01-08 Lead Discovery Center GmbH Dérivés de triazine disubstitués pharmaceutiquement actifs
US9242937B2 (en) 2011-03-02 2016-01-26 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted pyridine derivatives
AU2012244745A1 (en) * 2011-04-19 2013-09-19 Bayer Intellectual Property Gmbh Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines
TWI555737B (zh) * 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
EP2527332A1 (fr) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phényl-1,3,5-triazin-2-amines portant un groupe sulfoximine en tant qu'inhibiteurs de CDK9
JP5982490B2 (ja) 2011-09-16 2016-08-31 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 二置換５−フルオロ−ピリミジン
CA2848615C (fr) 2011-09-16 2020-02-25 Bayer Intellectual Property Gmbh Derives de 5-fluoropyrimidine disubstitues contenant un groupe sulfoximine
EP2909176B1 (fr) 2012-10-18 2016-07-20 Bayer Pharma Aktiengesellschaft Derives de n-(pyridin-2-yl)pyridin-2-amine contenant un group sulfone
ES2597232T3 (es) 2012-10-18 2017-01-17 Bayer Pharma Aktiengesellschaft 4-(orto)-fluorofenil-5-fluoropirimidin-2-il aminas que contienen un grupo sulfona
US9708293B2 (en) 2012-10-18 2017-07-18 Bayer Pharma Aktiengesellschaft N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
ES2622583T3 (es) 2012-11-15 2017-07-06 Bayer Pharma Aktiengesellschaft 4-(Orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
RS55580B1 (sr) 2012-11-15 2017-06-30 Bayer Pharma AG Derivati 5-fluoro-n-(piridin-2-il)piridin-2-amina koji sadrže sulfoksiminsku grupu
CA2917096C (fr) 2013-07-04 2021-05-18 Bayer Pharma Aktiengesellschaft Derives 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine substitues par un groupe sulfoximine et leur utilisation comme inhibiteurs de la cdk9 kinase
CN106232596A (zh) 2014-03-13 2016-12-14 拜耳医药股份有限公司 含有砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物

Also Published As

Publication number Publication date
GT201300293A (es) 2015-01-16
KR101958501B1 (ko) 2019-03-14
AR086552A1 (es) 2014-01-08
TW201249817A (en) 2012-12-16
CA2837027A1 (fr) 2012-11-29
EA023418B1 (ru) 2016-06-30
CN103702979A (zh) 2014-04-02
MX2013013711A (es) 2014-02-27
CA2837027C (fr) 2020-04-14
CU24175B1 (es) 2016-04-25
ECSP13013040A (es) 2014-01-31
PE20141075A1 (es) 2014-09-06
MX340803B (es) 2016-07-27
JP5955948B2 (ja) 2016-07-20
CR20130620A (es) 2014-02-04
US20170217949A1 (en) 2017-08-03
PL2714654T3 (pl) 2015-12-31
CL2013003360A1 (es) 2014-07-04
AP2013007254A0 (en) 2013-11-30
MY165748A (en) 2018-04-23
EP2714654B1 (fr) 2015-07-22
HRP20151060T1 (hr) 2015-11-06
IL229314A (en) 2017-01-31
IL229314A0 (en) 2014-01-30
CN103702979B (zh) 2016-09-28
TWI555737B (zh) 2016-11-01
AP3884A (en) 2016-11-05
ZA201309672B (en) 2022-03-30
EP2714654A1 (fr) 2014-04-09
TW201636330A (zh) 2016-10-16
ES2549529T3 (es) 2015-10-29
WO2012160034A1 (fr) 2012-11-29
US20140315906A1 (en) 2014-10-23
EA201301320A1 (ru) 2014-05-30
JO3204B1 (ar) 2018-03-08
SG194856A1 (en) 2013-12-30
BR112013029976A2 (pt) 2017-01-31
NZ617628A (en) 2014-12-24
CU20130157A7 (es) 2014-03-26
CO6811860A2 (es) 2013-12-16
JP2014515363A (ja) 2014-06-30
PT2714654E (pt) 2015-10-29
UY34095A (es) 2013-01-03
AU2012260983B2 (en) 2016-08-25
CY1116791T1 (el) 2017-03-15
RS54264B1 (en) 2016-02-29
ME02227B (me) 2016-02-20
TN2013000485A1 (en) 2015-03-30
SG10201606952XA (en) 2016-10-28
SI2714654T1 (sl) 2015-11-30
HUE027853T2 (en) 2016-11-28
KR20140041571A (ko) 2014-04-04
US9962389B2 (en) 2018-05-08
AU2012260983A1 (en) 2013-11-28
DOP2013000277A (es) 2014-04-15
DK2714654T3 (en) 2015-10-26
US9669034B2 (en) 2017-06-06
UA112870C2 (uk) 2016-11-10

Similar Documents

Publication Publication Date Title
MA35132B1 (fr) 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine
MA37942A2 (fr) Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
MA33731B1 (fr) Inhibiteurs du virus de l'hépatite c
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA38090A1 (fr) Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
MA35920B1 (fr) Composés destinés au traitement de l'amyotrophie spinale
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
MA37756A1 (fr) Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane
EA201390538A1 (ru) Противовирусные соединения
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA34147B1 (fr) Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
MA35039B1 (fr) Dérivés ramifiés de l'acide 3-phénylpropionique et leur utilisation
MA35804B1 (fr) Modulation de l'expression du virus de l'hepatite b (vhb)
MA33492B1 (fr) Inhibiteurs de bace
MA34392B1 (fr) Pyrimidines en tant qu'agents antiviraux
MA38091B1 (fr) Dérivés n-(pyridin-2-yl)pyrimidin-4-amines contenant un groupe sulfoximine
MA35443B1 (fr) Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c
MA38315A1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MA35444B1 (fr) Ligands du récepteur ep1
EA201170605A1 (ru) Циклоундекадепсипептидные соединения и применение указанных соединений в качестве лекарственного средства
EA201270798A1 (ru) Соединения для лечения гепатита с
MA38009A1 (fr) Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer
MA37999B1 (fr) Dérivés de macrolide, leur préparation et leur utilisation thérapeutique